MENU
+Compare
JANX
Stock ticker: NASDAQ
AS OF
Aug 11, 12:34 PM (EDT)
Price
$22.95
Change
+$0.11 (+0.48%)
Capitalization
1.37B

JANX Janux Therapeutics Forecast, Technical & Fundamental Analysis

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more

JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JANX with price predictions
Aug 08, 2025

JANX's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Indicator for JANX moved out of overbought territory on July 18, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on JANX as a result. In of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for JANX turned negative on July 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .

JANX moved below its 50-day moving average on August 06, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for JANX crossed bearishly below the 50-day moving average on August 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JANX advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .

JANX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 143 cases where JANX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JANX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.385) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). JANX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. JANX's P/S Ratio (3333.333) is very high in comparison to the industry average of (286.048).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

JANX is expected to report earnings to fall 4.69% to -52 cents per share on November 11

Janux Therapeutics JANX Stock Earnings Reports
Q3'25
Est.
$-0.52
Q2'25
Missed
by $0.09
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.18
The last earnings report on August 07 showed earnings per share of -55 cents, missing the estimate of -46 cents. With 190.82K shares outstanding, the current market capitalization sits at 1.37B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AIGOX36.190.31
+0.86%
Alger Growth & Income I-2
MIGYX63.350.45
+0.72%
Invesco Main Street Y
JAGRX62.110.40
+0.65%
Janus Henderson VIT Research Instl
LGCOX19.440.08
+0.41%
Lord Abbett Global Equity F3
FMCAX43.50-0.04
-0.09%
Fidelity Advisor Stock Selec Mid Cp M

JANX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with TERN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then TERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
+1.11%
TERN - JANX
37%
Loosely correlated
+7.80%
ATXS - JANX
36%
Loosely correlated
-6.15%
CRNX - JANX
36%
Loosely correlated
-3.69%
BNTX - JANX
35%
Loosely correlated
+0.28%
CYTK - JANX
35%
Loosely correlated
-3.23%
More